Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension

  • Futoshi Anan
  • Naohiko Takahashi
  • Tatsuhiko Ooie
  • Kunio Yufu
  • Masahide Hara
  • Mikiko Nakagawa
  • Hidetoshi Yonemochi
  • Tetsunori Saikawa
  • Hironobu Yoshimatsu
Clinical Trials



To compare the effects of combined therapy of an angiotensin II receptor blocker (ARB; valsartan) and an angiotensin converting enzyme inhibitor (ACEI; perindopril) on blood pressure (BP), metabolic profiles, plasma brain natriuretic peptide (BNP) levels, echocardiographic findings, and aortic pulse wave velocity (PWV) with those of respective monotherapy in never-treated patients with essential hypertension.


This was a prospective randomized trial, in which there were 31 patients with essential hypertension and left ventricular hypertrophy (LVH) who visited the outpatient clinic of Oita Red Cross Hospital (14 women and 17 men; mean±SD age, 59±5 years). Each patient was randomly assigned to receive valsartan (160 mg/day, V group, n=10), perindopril (8 mg/day, P group, n=11), or a combination of valsartan (80 mg/day) and perindopril (4 mg/day, V+P group, n=10) for 40 weeks. Ambulatory BP monitoring (ABPM), echocardiographic findings, metabolic findings, plasma BNP levels, and brachial-ankle PWV (baPWV) were evaluated before and after the 40-week therapy.


The baseline and post-therapeutic BP levels were similar among the three groups. At baseline ABPM, non-dipping was observed in 80, 82, and 80% in the V, P, and V+P groups, respectively. Each 40-week therapy regimen comparably reduced ABP. The plasma BNP levels (P<0.0001 for each), left ventricular mass index (LVMI) (P<0.01 for each), and PWV values (P<0.0001 for each) were also reduced. However, when compared with either V or P group, the percentage reduction in LVMI (P<0.05 and P<0.005, respectively), BNP (P<0.05 for each), and baPWV values (P<0.005 and P<0.001, respectively) was greater in the V+P group.


Our findings suggest that, when compared with each monotherapy, perindopril and valsartan combination therapy exerts greater beneficial effects regarding the regression of LVH, reduction in BNP, and improvement of PWV in a selected group of essential hypertensive patients with LVH and high prevalence of non-dipping patterns.


Perindopril Valsartan Left ventricular hypertrophy Brain natriuretic peptide Arterial stiffness 


  1. 1.
    Dahlof B, Devereux RB, Kjeldsen SE et al for the LIFE Study Group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003CrossRefPubMedGoogle Scholar
  2. 2.
    Fox KM (2003) EURopean trial on reduction of cardiac events with perindopril in stable coronary Artery disease investigators: efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362:782–788PubMedGoogle Scholar
  3. 3.
    Lonn E, Shaikholeslami R, Yi Q et al (2004) Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the heart outcome prevention evaluation (HOPE) Trial. J Am Coll Cardiol 43:2200–2206CrossRefPubMedGoogle Scholar
  4. 4.
    Stergiou GS, Skeva II, Baibas NM et al (2000) Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. J Cardiovasc Pharmacol 35:937–941Google Scholar
  5. 5.
    Mogensen CE, Neldam S, Tikkanen I et al (2000) Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321:1440–1444CrossRefPubMedGoogle Scholar
  6. 6.
    Rossing K, Christensen PK, Jensen BR et al (2002) Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 25:95–100PubMedGoogle Scholar
  7. 7.
    Koren MJ, Devereux RB, Casale PN et al (1991) Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114:345–352PubMedGoogle Scholar
  8. 8.
    Laurent S, Boutouyrie P, Asmar R et al (2001) Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37:1236–1241PubMedGoogle Scholar
  9. 9.
    Guerin AP, Blacher J, Pannier B et al (2001) Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 103:987–992PubMedGoogle Scholar
  10. 10.
    Safar ME, Levy BI, Strujiker-Boudier H (2003) Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 107:2864–2869CrossRefPubMedGoogle Scholar
  11. 11.
    Cuspidi C, Muiesan ML, Valagussa L et al for the CATCH investigators (2002) Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 20:2293–2300CrossRefPubMedGoogle Scholar
  12. 12.
    Rehman A, Rahman AR, Rasool AH (2002) Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors. J Hum Hypertens 16:261–266CrossRefPubMedGoogle Scholar
  13. 13.
    Pickering TG, Ad Hoc Panel (1996) Recommendations for the use of home (self) and ambulatory blood pressure monitoring. Am J Hypertens 9:1–11CrossRefPubMedGoogle Scholar
  14. 14.
    The Expert Committee on the Diagnosis of Diabetes Mellitus (1997) Diabetes Care 20:1183–1197PubMedGoogle Scholar
  15. 15.
    Tochikubo O, Ikeda A, Miyazima E et al (1996) Effect of insufficient sleep on blood pressure monitored by a new multimedical recorder. Hypertension 27:1318–1324PubMedGoogle Scholar
  16. 16.
    Kohara K, Igase M, Maguchi M et al (1996) Autonomic nervous function in essential hypertension in the elderly. Evaluation by power spectral analysis of heart rate variability. Am J Hypertens 9:1084–1089CrossRefPubMedGoogle Scholar
  17. 17.
    Verdecchia P, Schillaci G, Guerrieri M et al (1990) Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 81:528–536PubMedGoogle Scholar
  18. 18.
    Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMedGoogle Scholar
  19. 19.
    Nishikimi T, Yoshihara F, Morimoto A et al (1996) Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 28:22–30PubMedGoogle Scholar
  20. 20.
    Devereux RB, Alonso DR, Lutas EM et al (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57:450–458CrossRefPubMedGoogle Scholar
  21. 21.
    Verdecchia P, Schillaci G, Borgioni C et al (1998) Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97:48–54PubMedGoogle Scholar
  22. 22.
    Yamashina A, Tomiyama H, Takeda K et al (2002) Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 25:359–364CrossRefPubMedGoogle Scholar
  23. 23.
    Schillaci G, Verdecchia P, Porcellati C et al (2000) Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 35:580–586PubMedGoogle Scholar
  24. 24.
    Suzuki M, Hamada M, Yamamoto K et al (2002) Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res 25:669–676CrossRefPubMedGoogle Scholar
  25. 25.
    Mahmud A, Feely J (2002) Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 15:321–325CrossRefPubMedGoogle Scholar
  26. 26.
    Blaufarb IS, Sonnenblick EH (1996) The renin-angiotensin system in left ventricular remodeling. Am J Cardiol 77:8C–16CCrossRefPubMedGoogle Scholar
  27. 27.
    Pellacani A, Brunner HR, Nussberger J (1994) Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci 87:567–574Google Scholar
  28. 28.
    Nussberger J, Koike H (2004) Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil. Clin Ther 26(Suppl A):A12–A20CrossRefPubMedGoogle Scholar
  29. 29.
    Urata H, Kinoshita A, Misono KS et al (1990) Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265:22348–22357PubMedGoogle Scholar
  30. 30.
    Kim S, Iwao H (2000) Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52:11–34Google Scholar
  31. 31.
    Okin PM, Devereux RB, Jern S et al (2003) Losartan intervention for endpoint reduction in hypertension study investigations. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the losartan intervention for endpoint reduction in hypertension (LIFE) study. Circulation 108:684–690PubMedGoogle Scholar
  32. 32.
    Der Sarkissian S, Marchand EL, Duguay D et al (2003) Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril. Cardiovasc Res 57:775–783CrossRefPubMedGoogle Scholar
  33. 33.
    Anan F, Takahashi N, Ooie T et al (2004) Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. Metabolism 53:777–781CrossRefPubMedGoogle Scholar
  34. 34.
    Asmar R, Topouchian J, Pannier B et al (2001) Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. J Hypertens 19:813–818CrossRefPubMedGoogle Scholar
  35. 35.
    Barra JG, Levenson J, Armentano RL et al (1997) In vivo angiotensin II receptor blockade and converting enzyme inhibition on canine aortic viscoelasticity. Am J Physiol 272:H859–H868PubMedGoogle Scholar
  36. 36.
    Ghiadoni L, Virdis A, Magagna A et al (2000) Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 35:501–506PubMedGoogle Scholar
  37. 37.
    Kokkonen JO, Kuoppala A, Saarinen J et al (1999) Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase. Circulation 99:1984–1990PubMedGoogle Scholar
  38. 38.
    Anan F, Takahashi N, Ooie T et al (2003) Role of insulin resistance in nondipper essential hypertensive patients. Hypertens Res 26:669–676CrossRefPubMedGoogle Scholar
  39. 39.
    Richer C, Bruneval P, Menard J et al (1998) Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats. Hypertension 31:692–698PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Futoshi Anan
    • 1
    • 3
  • Naohiko Takahashi
    • 1
  • Tatsuhiko Ooie
    • 2
  • Kunio Yufu
    • 3
  • Masahide Hara
    • 1
  • Mikiko Nakagawa
    • 2
  • Hidetoshi Yonemochi
    • 2
  • Tetsunori Saikawa
    • 2
  • Hironobu Yoshimatsu
    • 1
  1. 1.Department of Internal Medicine 1, Faculty of MedicineOita UniversityOitaJapan
  2. 2.Department of Laboratory Medicine, Faculty of MedicineOita UniversityOitaJapan
  3. 3.Department of Cardiovascular DiseaseOita Red Cross HospitalOitaJapan

Personalised recommendations